Viral Conjunctivitis Pipeline Drugs Market to Exhibit a Thumping CAGR of 69.60% Between 2020 and 2023

Viral conjunctivitis, or “pink-eye”, is a highly contagious infection of the eye, wherein irritation, redness, watery discharge, and photophobia or light sensitivity are common symptoms. Currently, there is no approved treatment for this disease. Therefore, the use of viral conjunctivitis drugs is increasingly becoming mainstream, opening up a broad avenue for these medications. The market for viral conjunctivitis drugs will show an exceptional CAGR of 69.60% during the forecast period 2020-2023, when the projected revenue will reach US$462.4 mn by 2023.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12251

The report furnishes a combined analysis of primary and secondary research gathered from multiple sources, along with the projected market size for every drug that will be introduced in the market by 2023. The CAGR for every segment of the market is revealed. Competition between various existing and viral conjunctivitis drugs, future trends, demographics, epidemiological analysis, regulatory policies, and the overall market landscape have been described extensively. The key catalysts and challenges faced by the global viral conjunctivitis drugs market have been analyzed in the overview section.

The market forecast for the leading countries covers the period from the expected launch up to 2023, together with their respective CAGRs. The report includes significant factors such as the awaited launch date, the number of patients suffering from viral conjunctivitis, and product innovation in each country. The major companies have been profiled in the report, with emphasis on their recent developments, financial overview, business tactics, and product portfolio.

The global viral conjunctivitis drugs market can be broadly categorized according to region and type of drug. FST-100 and APD-209 are the chief drugs in the global viral conjunctivitis drug market. Of these, FST-100 will be more prominent by 2020, suggests TMR. The development of FST-100 was undertaken by a leading drug development company, Foresight Biotherapeutics Inc., which was later acquired by Shire Plc. when the drug was still under development. If approved, the drug will be the premier medication for the treatment of viral and bacterial eye infections, thus promising exhaustive opportunities in the global viral conjunctivitis drugs market.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=12251

However, APD-209, though rising in demand at a gradual rate, is likely to witness a higher demand than FST-100. Adenovir Pharma AB has been developing the drug, which is presently in its second stage.

According to regional segmentation, the viral conjunctivitis drugs markets in the U.K., Germany, the U.S., Japan, Brazil, and Australia are evaluated. Owing to the current clinical trials in the U.S., the country is expected to lead the other regions over the coming years. Extensive R&D activities, growing awareness about eye-related diseases, bright prospects of current clinical trials, and the presence of viral conjunctivitis diagnostic tests are few of the many catalysts promoting the U.S. viral conjunctivitis drug market. A favorable CAGR of 46.50% is expected during the forecast period in this regional segment.

As the demand for viral conjunctivitis drugs is multiplying, major companies are vigorously engaging in research activities so as to bring forth fruitful treatments and diagnostic tests for viral conjunctivitis. The key market players mentioned in the report are Allergan Plc, Panoptes Pharma GES.M.B.H., NovaBay Pharmaceuticals Inc., Shire Plc., NicOx S.A., NanoViricides Inc., and Adenovir Pharma AB.

Report Overview @ https://www.transparencymarketresearch.com/viral-conjunctivitis-pipeline-drugs-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.